# Impact of Beta Blockers on TAVI (BETA-TAVI)

Study · id `cardio:ct-nct05721170` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05721170](<https://clinicaltrials.gov/study/NCT05721170>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05721170

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 348 participants.

## Technical summary

Registry record NCT05721170. Randomized; no masking; primary purpose treatment. Start 2024-06-01 (actual); primary completion 2028-01-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 348 participants (planned count; ClinicalTrials.gov record NCT05721170, source copy `cardio:ctgov-nct05721170-2026-11-09`, retrieved 2026-11-18)
- Started: 2024-06-01 (actual) (ClinicalTrials.gov record NCT05721170, source copy `cardio:ctgov-nct05721170-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2028-01-30 (anticipated) (ClinicalTrials.gov record NCT05721170, source copy `cardio:ctgov-nct05721170-2026-11-09`, retrieved 2026-11-18)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT05721170, source copy `cardio:ctgov-nct05721170-2026-11-09`, retrieved 2026-11-18)
- Countries: Cyprus; Greece (ClinicalTrials.gov record NCT05721170, source copy `cardio:ctgov-nct05721170-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05721170-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: Impact of Beta Blockers on TAVI (BETA-TAVI)
- Acronym: BETA-TAVI
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Beta blocker
- Lead sponsor: National and Kapodistrian University of Athens
- Lead sponsor class: OTHER
- Collaborator: Evangelismos Hospital
- Collaborator class: OTHER
- Collaborator: Interbalkan Medical Center, Thessaloniki, Greece
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: National and Kapodistrian University of Athens (`cardio:org-national-and-kapodistrian-university-of-athens`)

## Provenance

Content hash: e2f19a3ed529dace4453b060217bffeba353ae5820cb24ae4dd097c79d5e6f3f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
